HJ-004-02
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HJ-004-02, covering 2026-01-22 to 2026-01-22. Get the full timeline:
Most recent: Clinical Trial Update: A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]